NDLI: Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.

Please wait, while we are loading the content...

Year: 2017 Volume: 80

Year: 2016 Volume: 79

Year: 2015 Volume: 78

Year: 2014 Volume: 77

Year: 2013 Volume: 76

Year: 2013 Volume: 76 Issue: 12

Year: 2013 Volume: 76 Issue: 11

Year: 2013 Volume: 76 Issue: 10

Year: 2013 Volume: 76 Issue: 9

Year: 2013 Volume: 76 Issue: 8

Year: 2013 Volume: 76 Issue: 7

Year: 2013 Volume: 76 Issue: 6

Year: 2013 Volume: 76 Issue: 5

An overview of the recent outbreaks of the avian-origin influenza A (H7N9) virus in the human.

Contrast-induced acute kidney injury in frail older people: what do we learn from the dilemma?

The importance of measuring impulsiveness in patients with addiction problems.

Recurrent pregnancy loss and thrombophilia in women with PCOS.

Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.

Carbon monoxide may enhance bile secretion by increasing glutathione excretion and Mrp2 expression in rats.

Short-term results of catheter-directed intrathrombus thrombolysis versus anticoagulation in acute proximal deep vein thrombosis.

Risk factors for acute kidney injury in the elderly undergoing contrast-enhanced computed tomography in the emergency department.

Fistula components of brain arteriovenous malformations: angioarchitecture analysis and embolization prior to gamma-knife surgery.

Correlation between thrombophilia and recurrent pregnancy loss in patients with polycystic ovary syndrome: a comparative study.

The reliability of the Chinese version of the Barratt Impulsiveness Scale version 11, in abstinent, opioid-dependent participants in Taiwan.

Effectiveness of botulinum toxin A in treatment of refractory erythromelalgia.

Hepatic inflammatory pseudotumor mimicking hepatocellular carcinoma.

Year: 2013 Volume: 76 Issue: 4

Year: 2013 Volume: 76 Issue: 3

Year: 2013 Volume: 76 Issue: 2

Year: 2013 Volume: 76 Issue: 1

Year: 2012 Volume: 75

Year: 2011 Volume: 74

Year: 2010 Volume: 73

Year: 2009 Volume: 72

Year: 2008 Volume: 71

Year: 2007 Volume: 70

Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Chen, Yuh-Min
Description	Author Affiliation: Chen YM ( Department of Chest Medicine, Taipei Veterans General Hospital, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC. ymchen@vghtpe.gov.tw)
Abstract	Lung cancer is the leading cause of cancer-related death in the world. Prior to the era of targeted therapy, platinum-based doublet chemotherapy was the first-line therapy of choice for patients with metastatic non-small-cell lung cancer (NSCLC). The availability of agents that target epidermal growth factor receptor (EGFR)-tyrosine kinase, as well as inhibitors against anaplastic lymphoma kinase (ALK) gene rearrangement or ROS-1 gene rearrangement product, has provided promising clinical benefits in specific subpopulations of NSCLC. At present, only first-generation EGFR-tyrosine kinase inhibitors (TKIs) (erlotinib and gefitinib) are available for clinical use. Second-generation irreversible EGFR-TKIs, such as afatinib, are still in clinical trials. In current clinical practice, EGFR-TKI is the first-line treatment of choice for metastatic NSCLC patients with tumor EGFR mutation or as salvage therapy in NSCLC patients who received systemic chemotherapy previously. Platinum-based doublet chemotherapy continues to be the standard of care for those treatment-naïve patients with EGFR wild -type tumor or unknown EGFR status. Even though all investigators agree with the use of EGFR-TKI as the first-line treatment in tumor EGFR-mutated patients, only 10-30% of NSCLC patients have mutated EGFR, and there was no obvious survival difference when EGFR-TKIs were used in a second-line setting versus a first-line treatment in EGFR-mutated patients. Thus, the molecular complexity of lung cancer emphasizes the need for optimizing treatment by seeking a more personalized approach to care, including searching for driver oncogenes, managing the emergence of resistance and overcoming that resistance, and optimizing the sequence of treatment. Numerous other novel targeted agents are now in clinical development, including new agents targeting novel pathways and those that may have the potential to overcome the limitations or resistance associated with currently available EGFR-TKIs. In this report, we review the clinical data of EGFR-TKIs as molecular-targeted therapies in NSCLC.
File Format	HTM / HTML
ISSN	17264901
e-ISSN	17287731
Journal	Journal of the Chinese Medical Association
Issue Number	5
Volume Number	76
Language	English
Publisher	Elsevier
Publisher Date	2013-05-01
Access Restriction	Open
Subject Keyword	Discipline Therapeutics Carcinoma, Non-small-cell Lung Drug Therapy Lung Neoplasms Protein Kinase Inhibitors Therapeutic Use Receptor, Epidermal Growth Factor Antagonists & Inhibitors Mutation Genetics
Content Type	Text
Resource Type	Article
Subject	Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Cost-effectiveness of epidermal growth factor receptor-targeting tyrosine kinase inhibitors.

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.

Targeted therapy for non-small-cell lung cancer: past, present and future.

Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.

First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?

The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.

Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.

Similar Documents

Cost-effectiveness of epidermal growth factor receptor-targeting tyrosine kinase inhibitors.

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.

Targeted therapy for non-small-cell lung cancer: past, present and future.

Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.

First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?

The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.

Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.